| Cancer name | Skin Cutaneous Melanoma |
| Cancer Type | SKCM |
| Immunotherapy type | Cancer Vaccine |
| Treatment | MAGEB2256-264 loaded DC |
| Drugstatus | NA |
| Drugbank ID | NA |
| Checkpoints | NA |
| Signature Type | Gene |
| Signature | AIRE |
| Official Symbol | NA |
| Mode of action | SNP_R_OTHER |
| Description for ‘mode of action’：the ‘mode of action’ for signature is composed of three parts: A_B_C. A describes the level at which the corresponding signature changes, it may contain the following values: TRAN(translation), PROT(protein), CE(cell), METH(methylation), AC(acetylation), PHOS(phosphorylation), MU(mutation), SNP(single nucleotide polymorphism), GLYC(glycosylation) and PATH(pathway). B describes the corresponding signature in which cancer immunotherapy condition group has changed, it may contain the following values: R (immunotherapy response group), NR(immunotherapy non-response group), D (Immunotherapy group), ND (No immunotherapy group). C describes the change detail (specific direction) of the corresponding signature, it may contain the following values: UP (High gene/protein expression or increased cellular abundance or enhanced epigenetic modification), DN (Low gene/protein expression or reduced cellular abundance or attenuated epigenetic modifications), LOSS (deletion mutation), GAIN (gain mutation)，Other. For example, the search/browse detail result for CD274 was “PROT_R_UP”, it can be interpreted that the protein level of CD274 was upregulated in immunotherapy response individuals. | |
| Experimental | mouse model |
| Description | To assess the in vivo relevance of AIRE functional differences related to rs1800522 SNP, B16F10 melanoma tumor growth was comparatively measured in mice from strain 1 and 2. Tumor growth was significantly (p<0.05) lower in strain 2 than in strain 1 mice until the 10th day from tumor challenge, but not at later stages. However, when both strains were immunized before tumor challenge with syngeneic DC pulsed with MAGEB2256-264peptide, melanoma tumor growth was significantly (p<0.05) lower in strain 2 than in strain 1 mice at all time-points. Interestingly, higher frequency of MAGEB2256-264 peptide-specific IFNγ secreting T cells and higher CD8+ T cell cytotoxic activity were observed in strain 2 than in strain 1 mice. AbstractTh:C allelic variant, protective in humans against melanoma, induced lower AIRE and MAGEB2 expression in C57BL/6 mouse mTECs than the T allele. Moreover, mTECs expressing the C allelic variant induced lower extent of apoptosis in MAGEB2-specific syngeneic T cells than mTECs bearing the T allelic variant (p < 0.05). Vaccination against MAGEB2 induced higher frequency of MAGEB2-specific CTL and exerted higher protective effect against melanoma development in mice bearing the CC AIRE genotype than in those bearing the TT one (p < 0.05). |
| PMID | 27563821 |
| Title | AIRE polymorphism, melanoma antigen-specific T cell immunity, and susceptibility to melanoma |